Compare IRS & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
Current Price
Current Price
| Metric | IRS | ALVO |
|---|---|---|
| Founded | 1943 | 2013 |
| Country | Argentina | Luxembourg |
| Employees | 1392 | 1460 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | IRS | ALVO |
|---|---|---|
| Price | $15.58 | $3.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 181.8K | ★ 416.9K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | ★ $3.66 | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.87 | $3.03 |
| 52 Week High | $19.14 | $11.85 |
| Indicator | IRS | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 45.58 |
| Support Level | $14.35 | $3.03 |
| Resistance Level | $16.10 | $3.93 |
| Average True Range (ATR) | 0.66 | 0.20 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 7.89 | 31.36 |
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.